Company Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Werner Cautreels Ph.D. |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267-759-3680 |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| CIK Code | 0001130598 |
| ISIN Number | US68232V8019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven M. Fruchtman M.D. | President and Chief Scientific Officer of Oncology |
| Mark Patrick Guerin CPA | Chief Financial Officer |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Executive Chairman |
| Dr. Werner Cautreels Ph.D. | Chief Executive Officer and Director |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Victor Moyo M.D. | Chief Medical Officer |
| Robert Redfield M.D. | Chief Medical Officer |
| C. David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Apr 16, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |